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sponsor. The GAIT ancillary trial was designed to be explor-
atory, and the hypothesis-generating procedure incorporated
the most accurate assumptions about OA disease progression
and outcome measures available at the time. Even today, the
optimal radiographic measure of disease progression in OA
remains a point of debate (2–5). The nonfluoroscopic MTP
view utilized in the current study was optimized by the
standard use of foot positioning templates at each visit to
obtain consistent tibial plateau alignment.
After recruitment for the GAIT study began, several
studies, including the GAIT ancillary trial, demonstrated that
the progression of OA (as assessed by radiographic JSN) was
substantially slower than had been assumed when GAIT
protocols were developed (6–8). These reports, in part, led to
our concerns about the limited power of the current study, as
was clearly indicated in our report. Brandt and colleagues
voice a concern about statistical precision, but not statistical
bias. We agree that precision, due to a combination of slower
disease progression and greater variability than predicted,
contributed to low power in the ancillary study. We find little
evidence to suggest that the nonfluoroscopic MTP view pro-
duced bias.
Contrary to the assertions made by Brandt et al, we did
not report trends indicating that any of the agents slowed JSN.
Within the context of the study’s limitations, however, the
observations we did report are as follows: there was no
significant difference in predefined joint space width (JSW)
loss between the treatment groups and the placebo group, and
regardless of treatment group, knees with K/L grade 2 OA
appeared to have less JSW loss and were less likely to progress
radiographically than knees with K/L grade 3 OA. In accor-
dance with the hypothesis-generating goals of this ancillary
study and the above observations, investigators designing
future OA trials evaluating structural modification will need to
include planning for a lower rate of progression and a smaller
loss in JSW over time than were assumed in past studies.
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No evidence yet to change American Heart Association
recommendations for poststreptococcal reactive
arthritis: comment on the article by van Bemmel et al
To the Editor:
In the recent article by van Bemmel et al, the authors
state that long-term antibiotic prophylaxis is not recommended
for adults who have poststreptococcal reactive arthritis (ReA),
based on their findings which indicated that there was no
increased risk of valvular heart disease in a prospective cohort
of white adult patients with poststreptococcal ReA (1). In fact,
although the effectiveness of prophylaxis has not been well
established, an American Heart Association class II recom-
mendation (level of evidence C) advises secondary prophylaxis
for up to 1 year after poststreptococcal ReA onset; then, if no
clinical evidence of carditis is observed, prophylaxis can be
discontinued (class I recommendation) (2). In our opinion,
considering the study design and the methodology utilized by
van Bemmel and colleagues (1), some points must be ad-
dressed and long-term prophylaxis reconsidered.
First, some inclusion criteria bias might have ham-
pered the results in the study by van Bemmel et al and,
therefore, the conclusions. The term “poststreptococcal ReA”
has been proposed in an attempt to define a homogeneous
group of patients who do not fulfill the revised Jones criteria
for acute rheumatic fever (ARF) (3); however, as in cases of
ARF, evidence of a recent group A -hemolytic streptococcal
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infection is mandatory for a diagnosis of poststreptococcal
ReA (4). In the 75 adult patients included in van Bemmel and
colleagues’ inception cohort, poststreptococcal ReA was diag-
nosed in patients with recent arthritis who also had fever,
cough, or angina preexisting before the development of arthri-
tis and serologic evidence of an antecedent streptococcal
infection determined by antistreptolysin O (ASO) titer; how-
ever, ASO testing was repeated in only 29 of 75 subjects (39%).
Antistreptococcal antibody titers can determine past but not
present group A streptococcal infections (2), and therefore
cannot be used alone in determining recent infection. To
document a recent group A streptococcal infection, antibody
tests should be obtained at 2–4-week intervals, thus confirming
a rising titer. In fact, patients with diseases other than ARF
and/or poststreptococcal ReA may also have increased strep-
tococcal antibody titers (3).
In addition, van Bemmel et al report that 30 patients
had arthritis combined with 2 minor Jones criteria. The
authors speculate that these subjects, even if they fulfill Jones
criteria, present some clinical characteristics that closely re-
semble poststreptococcal ReA, and therefore they were clas-
sified as having the disease. We completely agree with the
authors that the updated Jones criteria “are not a substitute for
clinical judgment,” but on the other hand, they should not be
used to formulate subjective clinical opinions. Therefore for
study purposes, if a recent group A streptococcal infection is
documented in patients, those patients who fulfill the Jones
criteria must be defined as having ARF and should receive
appropriate secondary prophylaxis. It would be interesting to
know if the 30 patients mentioned above had rising strepto-
coccal antibody titers at the time of disease onset. It is also
surprising that the exclusion of these 30 patients did not affect
the reported results in patients compared with controls, espe-
cially considering that the statistical approach used for a
population that is not homogeneous and has no apparent
Gauss distribution is a parametric test, such as the Student’s
t-test.
There are other methodologic issues that should also
be discussed. Van Bemmel and colleagues claim their study
was prospective, but the echocardiographic studies (the main
outcome measure) seem to have been completed using a
cross-sectional method. In fact, the tables that the authors
included report patient characteristics and ventricular mea-
surements at echocardiography, as well as valve morphology
and function, compared with controls, after a median followup
of 8.9 years. We can suppose, even if van Bemmel et al did
not specifically report it, that patients underwent echocardiog-
raphy at baseline and did not exhibit evidence of cardiac
involvement; otherwise, ARF, and not poststreptococcal ReA,
would be the final diagnosis. However, the authors did not
specify whether echocardiographic values obtained in pa-
tients at followup were significantly different from those
obtained at baseline. A prospective, paired comparative study
design with evaluation at onset, after 1 year, and at the final
followup might have been more suitable for the study, which
was designed to assess the development of valvular heart
disease over time in a poststreptococcal ReA cohort without
prophylaxis.
The authors statement, “considering the different clin-
ical and genetic characteristics of poststreptococcal ReA and
ARF,” could be reductive and possibly confounding (5). None-
theless, van Bemmel and colleagues speculate that some cases
of poststreptococcal ReA closely resemble ARF, although
their clinical judgment prompted them to consider these
patients as having poststreptococcal ReA, which means the
patients did not receive antibiotic prophylaxis. It is still not
clear whether poststreptococcal ReA represents a distinct
syndrome or is a manifestation of ARF, and as far as we know,
the debate is still open (2).
In our own rheumatology units, we are monitoring the
cases of 52 children with poststreptococcal ReA identified
according to previously published criteria (4), who have been
described in part in a previous report (6). None of the patients
with poststreptococcal ReA enrolled in that study fulfilled the
updated Jones criteria for the diagnosis of ARF (3); they did
not show major manifestations of ARF other than arthritis,
and only one possible minor criterion, an increase of acute-
phase reactant levels, was observed. All children with post-
streptococcal ReA were followed up for a median of 8 years
(range 6 years, 4 months–10 years, 3 months), and presented
with an initial episode of arthritis, with evidence of an ante-
cedent group A streptococcal infection. Streptococcal antibody
tests (ASO and anti–DNase B) were performed on the serum
of all patients at the time of initial presentation, and were
subsequently repeated 3 weeks after the onset of arthritis. In
all patients, the level of at least 1 antibody was significantly
elevated (at least 2.5 times above the upper limit of normal),
and in 49 of the 52 patients, levels of both antibodies were
elevated. The clinical and laboratory findings of the patients
are summarized in Table 1. All patients underwent a complete
cardiac evaluation, with electrocardiography and color Dopp-
ler echocardiography performed by a pediatric cardiologist at
the time of disease onset, at followup at 1 year, and at the final
recorded followup. None of the patients developed clinical or
echocardiographic evidence of valvular disease or cardiac
involvement at the time of disease onset or during followup. As
recommended (2), all children received intramuscular benza-
Table 1. Clinical and laboratory characteristics of the 52 children
with poststreptococcal ReA*
Sex, no. female/male 23/29
Age at disease onset, years 9.17 (4.83–15.33)
Preceding sore throat, no. 36
Onset of arthritis after pharyngitis, days 9 (4–12)
Duration of arthritis from onset to resolution
of symptoms, days
54 (7–153)
No. of swollen joints 2 (1–5)
Distribution of involved joints, no.
Monarthritis involving 1 large joint (knee,
ankle, or hip)
19
Arthritis involving 2 or 3 joints 29
Arthritis involving 3 joints 4
Arthritis, no. migratory/nonmigratory 15/37
ASO, mean  SEM IU/ml 1,280  205
Anti–DNase B, mean  SEM IU/ml 1,020 125
ESR, mm/hour (normal 25) 42 (28–57)
CRP, mg/dl (normal 0.35) 3.4 (1.8–5.4)
* Except where otherwise indicated, values are the median (range).
ReA  reactive arthritis; ASO  antistreptolysin O; ESR  erythro-
cyte sedimentation rate; CRP  C-reactive protein.
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thine penicillin prophylaxis, which was discontinued after 1
year, since evidence of carditis was not detected.
We agree with van Bemmel et al that abnormal cardiac
findings following poststreptococcal ReA are extremely rare,
although it has been previously reported that a small propor-
tion of patients with poststreptococcal ReA may subsequently
develop carditis (4,7,8), making poststreptococcal ReA part of
the spectrum of ARF. In children with arthritis following a
group A streptococcal infection, who did not fulfill the revised
Jones criteria at the time of disease onset, we do not consider
it crucial to differentiate poststreptococcal ReA from ARF,
but it does seem judicious to follow the recommendations of
the American Heart Association and administer secondary
prophylaxis to patients with poststreptococcal ReA for a
period of 1 year (2). If carditis develops, the patient should be
reclassified as having ARF and should continue to receive
secondary prophylaxis. If carditis does not develop, prophy-
laxis can be discontinued in the patient, who was correctly
classified as having poststreptococcal ReA.
Notably, the study by van Bemmel et al was completed
using adult patients, while most of our recommendations
derive from observations in pediatric studies. However, we do
not think that there are major differences between populations
of adults and children, apart from a different group A strep-
tococcal infection rate seen in children. We believe that the
main question, i.e., whether to use prophylaxis in patients with
poststreptococcal ReA, can be answered only in a controlled
study, and that until such time, there is no evidence to suggest
that the recommendations of the American Heart Association
should be changed.
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Reply
To the Editor:
We congratulate Dr. Simonini and colleagues on their
study, in which they used serial echocardiography to investi-
gate poststreptococcal ReA in 52 children. Those patients were
treated with benzylpenicillin, and during followup, no echocar-
diographic evidence of valvular disease was observed. There-
fore, these data suggest that treatment with benzylpenicillin
effectively reduces the risk of carditis in children.
The aim of our study was not to examine the efficacy of
benzylpenicillin in preventing carditis. Our goal was to deter-
mine the increased risk of carditis (previously unknown) in
adult patients with poststreptococcal ReA. Studies on ARF
have shown that the risk of carditis in adults is lower than in
children (33% versus 50%) (1–3). In children with poststrep-
tococcal ReA, the risk of carditis is 8% (1–3), and in adults,
as mentioned above, the risk had yet to be determined.
This led us to study the frequency of valvular heart
disease in an unselected cohort of adult patients with post-
streptococcal ReA, with a median followup of 8.9 years. Since
none of these patients were treated with benzylpenicillin, the
data presented in our report were an estimation of the natural
course of the disease. As such, the aim of our study was
different than that of the study by Simonini and colleagues. We
observed no increased frequency of valvular heart disease in
patients, compared with matched controls.
We completely agree with Simonini et al that it would
have been more convenient to have serial ASO and anti–
DNase B measurements. Unfortunately, serial serologic mea-
surements, as well as throat cultures, had not been performed
in all cases at the time of enrollment, which began in 1993. In
our study, 2 patients were diagnosed as having ARF because
they each fulfilled 2 major Jones criteria; these patients were
treated with antibiotic prophylaxis and excluded from the
study. Additionally, 30 patients with poststreptococcal ReA
could have been classified, according to the Jones criteria, as
having ARF, based on the fact that they fulfilled 1 major Jones
criterion (arthritis, although not strictly a polyarthritis in our
study) and 2 minor criteria (fever, increased erythrocyte
sedimentation rate/C-reactive protein). These 30 patients had
an arthritis that was atypical in its time of onset and duration
and in its localization and that did not exhibit a dramatic
response to antiinflammatory agents. Therefore, we catego-
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